Compare PROF & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROF | DHY |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | United States |
| Employees | 142 | N/A |
| Industry | Medical/Dental Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.7M | 208.3M |
| IPO Year | 2017 | 1998 |
| Metric | PROF | DHY |
|---|---|---|
| Price | $7.34 | $1.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 145.3K | ★ 556.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $10,680,000.00 | N/A |
| Revenue This Year | $61.09 | N/A |
| Revenue Next Year | $120.94 | N/A |
| P/E Ratio | $6.41 | ★ N/A |
| Revenue Growth | ★ 48.35 | N/A |
| 52 Week Low | $3.90 | $1.82 |
| 52 Week High | $8.95 | $2.16 |
| Indicator | PROF | DHY |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 31.83 |
| Support Level | $7.00 | N/A |
| Resistance Level | $7.95 | $2.14 |
| Average True Range (ATR) | 0.42 | 0.02 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 65.32 | 5.00 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.